Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Sells $660,757.50 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 16,315 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares in the company, valued at approximately $1,267,731. This trade represents a 34.26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Ian Mortimer also recently made the following trade(s):

• On Friday, January 24th, Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60.

Xenon Pharmaceuticals Trading Up 0.5 %

Shares of NASDAQ:XENE opened at $40.19 on Thursday. The firm has a 50 day simple moving average of $40.26 and a 200-day simple moving average of $40.80. Xenon Pharmaceuticals Inc. has a twelve month low of $35.53 and a twelve month high of $50.99. The company has a market capitalization of $3.06 billion, a PE ratio of -14.25 and a beta of 1.20.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.01. During the same period last year, the firm posted ($0.73) EPS. As a group, equities research analysts predict that Xenon Pharmaceuticals Inc. will post -3.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC reissued a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Raymond James reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $56.00.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several large investors have recently modified their holdings of the company. Loomis Sayles & Co. L P boosted its stake in Xenon Pharmaceuticals by 7.1% during the 3rd quarter. Loomis Sayles & Co. L P now owns 707,222 shares of the biopharmaceutical company’s stock worth $27,843,000 after purchasing an additional 46,964 shares during the period. Vestal Point Capital LP raised its holdings in shares of Xenon Pharmaceuticals by 57.1% in the third quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company’s stock valued at $32,480,000 after buying an additional 300,000 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Xenon Pharmaceuticals by 4.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 439,074 shares of the biopharmaceutical company’s stock worth $17,287,000 after buying an additional 17,953 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Xenon Pharmaceuticals by 1,263.2% during the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock worth $38,456,000 after buying an additional 905,129 shares during the last quarter. Finally, Barclays PLC increased its position in Xenon Pharmaceuticals by 1,275.5% in the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $590,000 after acquiring an additional 13,903 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.